Home Infusion Therapy Pharmacy - 3336H0001X
Customize your policy alerts
Sign up for Home Infusion Therapy Pharmacy - 3336H0001X policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Pharmacy-based, decentralized patient care organization with expertise in USP 797-compliant sterile drug compounding that provides care to patients with acute or chronic conditions generally pertaining to parenteral administration of drugs, biologics and nutritional formulae administered through catheters and/or needles in home and alternate sites. Extensive professional pharmacy services, care coordination, infusion nursing services, supplies and equipment are provided to optimize efficacy and compliance.
| Field | Value |
|---|---|
| Code | 3336H0001X |
| Grouping | Suppliers |
| Classification | Pharmacy |
| Specialization | Home Infusion Therapy Pharmacy |
| Category | Non-Individual |
NPI Registrations
2.6K NPIs are registered under this taxonomy code nationwide.
The table below splits that total by NPI type — Type 1 covers individual practitioners, Type 2 covers organizations and facilities — followed by the five states with the most NPIs registered under this taxonomy code.
Medicare: Top Billing Codes by Claims
Medicare claims nationally billed by providers whose primary NUCC taxonomy is this code, broken down by billing code. This is a narrower population than the NPI Registrations count above, which includes providers holding this code as a secondary specialty — the two sections are not directly comparable. Source: CMS Medicare Physician & Other Practitioner by Provider and Service data.
31 rows
| Code | Description | Avg Paid | Claims |
|---|---|---|---|
| K1034 | K1034 – Provision of covid-19 test, nonprescription self-administered and self-collected use, fda ap… | $12 | 64.7K |
| J2278 | J2278 – Injection, ziconotide, 1 microgram | $7 | 53.5K |
| J1569 | J1569 – Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | $36 | 42.2K |
| G0069 | G0069 – Professional services for the administration of subcutaneous immunotherapy or other subcutan… | $21 | 26.7K |
| J1170 | J1170 – Injection, hydromorphone, up to 4 mg | $3 | 16K |
| J7999 | J7999 – Compounded drug, not otherwise classified | $228 | 13.1K |
| J0475 | J0475 – Injection, baclofen, 10 mg | $141 | 13.1K |
| J2274 | J2274 – Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | $10 | 10.7K |
| G0068 | G0068 – Professional services for the administration of anti-infective, pain management, chelation,… | $43 | 7.9K |
| A4220 | A4220 – Refill kit for implantable infusion pump | $15 | 6.8K |
Showing 1–10 of 31
Medicare: Top Providers by Revenue
The highest-revenue Medicare providers whose primary NUCC taxonomy is this code. This list can overlap with the Medicaid list below — a provider can rank highly in both programs.
Medicaid: Revenue by Year
Medicaid: Top Billing Codes by Claims
Medicaid claims billed by providers whose primary NUCC taxonomy is this code, broken down by state. This is a narrower population than the NPI Registrations count above, which includes providers holding this code as a secondary specialty — the two sections are not directly comparable. Source: state Medicaid claims data.
540 rows
| Code | Description | Avg Paid | Claims |
|---|---|---|---|
| S9342 | S9342 – Home therapy; enteral nutrition via pump; administrative services, professional pharmacy ser… | $45 | 2.9M |
| B4035 | B4035 – Enteral feeding supply kit; pump fed, per day, includes but not limited to feeding/flushing… | $95 | 2.2M |
| 99601 | 99601 – The provider visits the patient at home to provide an infusion or administer a specialty dru… | $86 | 1M |
| S9500 | S9500 – Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; ad… | $121 | 786.3K |
| A4223 | A4223 – Infusion supplies not used with external infusion pump, per cassette or bag (list drugs sepa… | $120 | 713K |
| S9340 | S9340 – Home therapy; enteral nutrition; administrative services, professional pharmacy services, ca… | $61 | 667.7K |
| B4034 | B4034 – Enteral feeding supply kit; syringe fed, per day, includes but not limited to feeding/flushi… | $51 | 646K |
| A4221 | A4221 – Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separa… | $24 | 627.5K |
| B4160 | B4160 – Enteral formula, for pediatrics, nutritionally complete calorically dense (equal to or great… | $143 | 613.4K |
| B4161 | B4161 – Enteral formula, for pediatrics, hydrolyzed/amino acids and peptide chain proteins, includes… | $458 | 489.1K |
Showing 1–10 of 540
Medicaid: Top Providers by Revenue
The highest-revenue Medicaid providers whose primary NUCC taxonomy is this code. This list can overlap with the Medicare list above — a provider can rank highly in both programs.
| Provider | State | Revenue |
|---|---|---|
| INDIANA UNIVERSITY HEALTH, INC | IN | $178.1M |
| JOHNS HOPKINS PHARMAQUIP INC | MD | $81.7M |
| CHILDREN'S HOSPITAL MEDICAL CENTER | OH | $57M |
| TWELVESTONE MEDICAL, INC. | TN | $52.6M |
| TRINITY HOMECARE LLC | NY | $46.8M |
| OPTION CARE ENTERPRISES, INC. | IL | $45.5M |
| PROVIDENCE HEALTH & SERVICES - WASHINGTON | WA | $41.8M |
| BEST OPTION HEALTHCARE PUERTO RICO LLC | PR | $41.5M |
Frequently Asked Questions
References
- 1.NPI Registry. Centers for Medicare & Medicaid Services (CMS), National Plan and Provider Enumeration System (NPPES). Retrieved Aug 11, 2026.The public NPPES lookup tool for verifying a provider's National Provider Identifier, practice address, and taxonomy classification.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.